Generics US generics major Mylan (Nasdaq: MYL) has confirmed that, along with its subsidiary Mylan Pharmaceuticals, it been sued by Japanese drugmaker Shionogi's (TKO: 4507) US unit and CIMA Labs (which provide the drug delivery technology) in connection with the filing of an Abbreviated New Drug Application with the US Food and Drug Administration for a copy version of their Orapred ODT (prednisolone sodium phosphate) orally disintegrating tablets, 10mg, 15mg and 30mg. The product is indicated as an anti-inflammatory or immunosuppressive agent for the treatment of certain endocrine conditions and for palliation of certain neoplastic conditions. 20 December 2010